Becton Dickinson (NYSE:BDX) sells basic healthcare products such as needles, surgical tools and syringes. It also sells products that are used in drug discovery and related lab functions. Sales aren't growing rapidly, but management has been able to control costs to boost earnings in the double digits annually. Going forward, investors should expect more than the same, and the stock looks very reasonably valued currently.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

Recent Developments
Becton held an analyst day last fall, where it revealed details on its expected business trends over the next few years. The company sees growth in emerging markets, through the introduction of new products, and from acquisitions. It also plans to continue to cut costs and improve its cost structure through initiatives such as making its supply chain more efficient. On the new product front, it has continually reinvested sales into research and development. R&D expense is projected to triple to 18% by fiscal 2014 from 2009 levels of 6%.

The company's recent history suggests it should be able to continue to deliver on its goals. Since 2004, profit margins have steadily improved. Operating margins have increased from around 15% to above 20% over the last twelve months. Sales growth has been somewhat modest at 6.1% over the past five years, but the cost controls have allowed it to leverage this into annual profit growth close to 14%.

SEE: A Look At Corporate Profit Margins

Outlook and Valuation
For all of 2012, analysts project modest sales growth of 1.8% and total sales just below $8 billion. The current projections are for 2013 top-line growth of 3.6% and total sales of nearly $8.3 billion. Profit projections for these two annual periods are $5.70 and $6.19, respectively, and represent forward earnings multiples of 12.8 times and 11.8 times, respectively. This is well below Becton's five-year average of 16.4 and below the forward market multiple of 12.9.

The Bottom Line
Becton's rivals include CR Bard (NYSE:BCR), Baxter International (NYSE:BAX), CareFusion (NYSE:CFN) and PerkinElmer (NYSE:PKI). Only Baxter trades at a lower forward multiple for the coming year but has had some safety issues with some of its products. All over a high degree of sales stability, but Becton stands out for having one of the clearest growth strategies in the field as well as a solid track record of delivering on its goals.

At the time of writing, Ryan C. Fuhrmann did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  2. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  3. Investing News

    7 Stocks That Could Surprise in 2016

    Here are seven stocks that could be good additions to your portfolio in 2016.
  4. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  5. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  6. Investing News

    Hillary Clinton's Liberal Orthodoxy

    Clinton's economic agenda laid out in July is divided into three broad groups: strong growth, fair growth and long-term growth. And her overarching goal is to "give working families a raise."
  7. Personal Finance

    Zika Virus: Latest Advice on Staying Safe

    Zika has hit the U.S. Here’s the most recent update on what’s known about the virus, how it spreads, who’s at highest risk and how to avoid it.
  8. Stock Analysis

    Hologic: An Activist Investment Analysis (HOLX)

    Read about a health care company that attracted activist investors Carl Icahn, Barry Rosenstein and Ralph Whitworth at the same time.
  9. Investing

    How To Make Sure Your Healthcare Costs Do Not Ruin Your Retirement

    The best proactive plan of action for a stable retirement is to understand medical costs, plan ahead, invest properly, and consider supplemental insurance.
  10. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
RELATED FAQS
  1. Does dental insurance cover implants?

    Dental implants have become a widely used procedure in dentistry. Despite their popularity, however, they tend to not be ... Read Full Answer >>
  2. Does dental insurance cover dentures?

    Most full dental insurance policies include some restorative coverage, usually meaning that up to 50% of the cost of dentures ... Read Full Answer >>
  3. Can CareCredit be used for family members?

    CareCredit has become a widely used option when it comes to paying for medical procedures, primarily procedures not typically ... Read Full Answer >>
  4. Can a Flexible Spending Account (FSA) be used for dental?

    Flexible Spending Accounts (FSAs) can be used to pay for dental expenses including deductibles and co-payments with pretax ... Read Full Answer >>
  5. Does dental insurance cover braces?

    Most regular dental plans cover little to none of the costs of braces. The primary focus of regular dental plans is prevention ... Read Full Answer >>
  6. Is dental insurance tax deductible?

    Dental insurance premiums may be tax deductible. To be deductible as a qualifying medical expense, the dental insurance must ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center